EP0804169A1 - Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures - Google Patents

Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures

Info

Publication number
EP0804169A1
EP0804169A1 EP95944048A EP95944048A EP0804169A1 EP 0804169 A1 EP0804169 A1 EP 0804169A1 EP 95944048 A EP95944048 A EP 95944048A EP 95944048 A EP95944048 A EP 95944048A EP 0804169 A1 EP0804169 A1 EP 0804169A1
Authority
EP
European Patent Office
Prior art keywords
nsaid
composition
gum
weight
hydrocouoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95944048A
Other languages
German (de)
English (en)
Other versions
EP0804169A4 (fr
Inventor
Eric H. Kuhrts
David R. Friend
Karen Yu
Jagdish Parasrampuria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cibus Pharmaceutical Inc
Original Assignee
Cibus Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cibus Pharmaceutical Inc filed Critical Cibus Pharmaceutical Inc
Publication of EP0804169A1 publication Critical patent/EP0804169A1/fr
Publication of EP0804169A4 publication Critical patent/EP0804169A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Definitions

  • This invention relates to mucosal protective pharmaceutical compositions comprising an NSAID, a hydrocoUoid gum and other excipients.
  • the invention also relates to a process for preparing such compositions and a method for treating certain conditions in humans by administering the compositions.
  • Non-steroidal anti-inflammatory drugs including aspirin have been used successfully in large numbers of patients with arthritis (including rheumatoid and osteoarthritis), and dysmenorrhea to relieve mild to moderate pain. It is well recognized that NSAIDs have a high incidence of gastrointestinal (GI) side effects. Serious GI adverse events such as bleeding, ulceration, and perforation can occur at any time in patients treated with regular doses of aspirin or other NSAIDs. The incidence of such adverse events ranges from 1-4% for studies without routine endoscopic surveillance to about 16% in studies where patients undergo regular endoscopic assessments.
  • GI gastrointestinal
  • Polysaccharide gums of hydrocolloids are a diverse class of substances that are hydrophilic and swell when in contact with water. When hydrated, they exhibit various degrees of viscosity. Polysaccharide hydrocolloids may contain galactose, galacturonic acid residues, mannose and sometimes xylose and arabinose. Structurally, they are similar to hemicellulose and when dissolved in water produce mucilage or gel.
  • Some common polysaccharides used in the food and pharmaceutical industry are pectin, galactomannan gums, such as guar gum and locust bean gum, algal polysaccharides, such as agar and carrageenan, modified celluloses such as the cellulose ethers and esters and bacterial gums such as xanthan.
  • pectin galactomannan gums
  • algal polysaccharides such as agar and carrageenan
  • modified celluloses such as the cellulose ethers and esters
  • bacterial gums such as xanthan.
  • the viscosity of these various substances will vary depending upon their molecular weight and structure.
  • a significant problem associated with high-viscosity water-soluble polymers is their ability to hydrate. Hydration is particularly difficult when these polymers are compressed into solid dosage forms. Most of the polymers used as excipients in pharmaceutical dosage forms are used at fairly low levels (e.g., 2 to 5 weight %) and principaUy as fUlers or diluents. Of aU the water-soluble polymers, guar gum probably possesses the highest molecular weight and exhibits the greatest viscosity when hydrated.
  • Guar gum has been used at such low levels in a variety of products such as Quinidex ® brand quinidine sulfate, Sine-Off ® brand aspirin and acetaminophen, Bayei ® brand aspirin, and Premarin ® brand estrogen tablets. No mucosal protective effect has been reported at such low doses.
  • the molecular weight of guar gum is reported as in the range of 1-2 x 10° daltons (J. Chromatogr. 1981; 206, 410 and Carbohvd. Polymers. 1984; 4,299).
  • hydrocolloids which come within the above limitations include solid dosage forms that contain about 5 % by weight of high-viscosity gel-forming polysaccharides and are subject to surface gelation and the inabUity to fully hydrate the dosage form. Tablets containing elevated levels of high-viscosity polysaccharides begin to gel and hydrate, but the hydration stops at a certain point. The core of the tablet remains dry and therefore not all the drug may be released. The dissolution tests of such tablets demonstrate that only 40% to 70% of the drug is actually released after eight hours and, in many cases, even after 24 hours a significant amount of the drug is not released.
  • tablets containing high amounts of high-viscosity polysaccharides when formulated differently, can result in dose dumping or the immediate release of the drug, and therefore cannot be used for sustained release formulations, because they immediately disintegrate upon reaching the stomach or in a dissolution vessel.
  • An object of this invention is to provide a pharmaceutical composition containing a NSAID that exhibits reduced gastric irritation when delivered to a subject orally, as compared to presently available NSAID compositions.
  • Another object of this invention is to provide a pharmaceutical composition containing a NSAID that releases the NSAID at essentially the same rate and level as commerciaUy avaUable NSAID compositions, i.e. the composition does not alter pharmacokinetic profile of the NSAID.
  • Another object of this invention is to provide a pharmaceutical composition containing a NSAID that disperses in the stomach and upper GI tract quickly to ensure release of the NSAID and at the same time provide mucosal protection.
  • Another object of this invention is to provide a pharmaceutical composition containing a NSAID that meets the above objectives and can be prepared as a tablet or capsule.
  • Another object of this invention is to provide a pharmaceutical composition containing a NSAID that meets the above objects and is readily prepared using inexpensive, commerciaUy avaUable materials combined in a unique manner.
  • Still another object of this invention is to provide a pharmaceutical composition containing a NSAID that is prepared without using components that increase the difficulty of handling and storing the compositions of this invention.
  • Still another object of this invention is to provide a method for reducing the gastric irritancy of NSAID - containing compositions by including a mucosal protective amount of a hydrocoUoid obtainable from higher plants in the composition.
  • One aspect of this invention is a pharmaceutical composition suitable for oral delivery of a non-steroidal anti-inflammatory drug (NSAID) as a unit dosage form, which composition exhibits a mucosal protective effect and which comprises
  • NSAID non-steroidal anti-inflammatory drug
  • a therapeutically-effective amount of a NSAID is a method for reducing the gastric irritation effect of an NSAID whUe orally administering that NSAID, which method comprises orally administering a unit dosage form composition comprising
  • StUl another aspect of this invention is a process for preparing an oraUy- administrable unit dosage form of an NSAID that has reduced gastric irritation, which process comprises combining a therapeutically-effective amount of the NSAID with an amount of a pharmaceutically-acceptable hydrocoUoid obtainable from higher plants that is sufficient to decrease the gastric irritation effect of the NSAID when the NSAID-containing composition is orally administered.
  • mucosal protective formulations comprising a solid dose of (a) a NSAID in a physiologically desirable amount, (b) a high viscosity, substantially linear, polysaccharide hydrocoUoid (generally consisting of long mannan molecules with some side chain attachment as exemplified by guar gum and locust bean gum or other polysaccharides such as gum tragacanth or karaya gum) by itself or in conjunction with (c) another dispersion-enhancing excipient, where both the NSAID and the high viscosity hydrocoUoid may be coated with lower viscosity hydrocolloids, particularly cellulosic.
  • a NSAID in a physiologically desirable amount
  • a high viscosity, substantially linear, polysaccharide hydrocoUoid generally consisting of long mannan molecules with some side chain attachment as exemplified by guar gum and locust bean gum or other polysaccharides such as gum tragacanth or
  • NSAID pharmaceutical composition that exhibits mucosal protective characteristics in a vertebrate animal to which it is orally administered and that comprises (a) a therapeutically effective amount of an NSAID absorbable through the upper gastrointestinal tract, (b) an amount of a powdered hydrocoUoid gum obtainable from higher plants that results in a mucosal protective effect in the gastrointestinal system with drug transport to the subject's blood stream, and (c) other pharmaceutically-acceptable excipients that enhance the dispersion of drug and hydrocoUoid in the stomach to provide the desired mucosal protective effect.
  • Another aspect of this invention is a soUd dosage form NSAID pharmaceutical composition for administration to a human subject comprising , (a) 15% to 90% (w/w) of a powdered hydrocolloidal gum obtainable from higher plants (generally having a viscosity when fully hydrated of at least 75 cps for a 1 % neutral aqueous solution at 25°C), (b) 10% to 75 % (w/w) of another pharmaceuticaUy acceptable, dispersion-enhancing excipient, and (c) a therapeutically-effective amount of an NSAID that is absorbable through the upper gastrointestinal tract .
  • a powdered hydrocolloidal gum obtainable from higher plants (generally having a viscosity when fully hydrated of at least 75 cps for a 1 % neutral aqueous solution at 25°C)
  • b 10% to 75 % (w/w) of another pharmaceuticaUy acceptable, dispersion-enhancing excipient
  • this invention can be viewed as an improvement in a composition comprising a therapeutically effective amount of an NSAID suitable for oral administration to a human subject in need thereof in combination with a suitable pharmaceutical excipient.
  • the improvement comprises the combination of the NSAID with a powdered hydrocoUoid gum obtainable from higher plants in an amount sufficient to provide a cytoprotective effect, i.e., to reduce the ulcerogenic effect of the NSAID.
  • hydrocolloids used in the subject invention have high viscosity exhibited upon hydration, are normally linear (at least about 50% by weight or more of the compound is the backbone chain), and will normally have a high molecular weight, usually at least about 5 x 10 3 daltons, more usually greater than about 1 x 10° daltons.
  • the hydrocoUoid is a powdered hydrocoUoid gum that is obtainable from higher plants and that exhibits a viscosity at 1 % concentration in a neutral aqueous solution of at least about 75 centipoise per second (cps) at 25 °C after 24 h, using a Brookfield Viscometer (model LVF) with a #3 spindle at 90 rpm, preferably at least about 1 x 10 3 centipoise (cps), and most preferably at least about 2 x 10 3 cps. See Meer Corp., An Introduction to Plant Hydrocolloids.
  • higher plant an organism of the vegetable kingdom that lacks the power of locomotion, has cellulose cell walls, grows by synthesis of or inorganic substances and includes the vascular plants (or Tracheophytes) of the division Spermatophyta, particularly those of the class Angiospermae.
  • the gums may be extracted from the roots, legumes, pods, berries, bark, etc.
  • higher plants do not include algae, flagellates, bacteria, slime molds, fungi, mosses, ferns, horsetails, and the like.
  • Representative hydrocoUoid gums obtainable from higher plants include guar gum, gum tragacanth, karaya gum (also referred to as karaya gum) and locust bean gum.
  • HydrocoUoid gums most useful are those where the hydrocoUoid is a polysaccharide hydrocoUoid which is chemically designated as a galactomannan.
  • Galactomannans are polysaccharides consisting of long chains of (1 ⁇ 4) - 3-D-mannopyranosyl units to which single unit side chains of ⁇ -D- galactopyranosyl are joined by (1 ⁇ 6) Unkages.
  • Galactomannans are found in a variety of plants but differ in molecular size and the number of D-galactosyl side chains.
  • the galactomannans useful in this invention are commonly found in the endosperms of the leguminosae. Examples of the family of legumes are set forth in Table 1 which shows the family and the percent endosperm content of leguminous seeds.
  • Baryxylum 30 Indigofera 20
  • Table 2 shows the approximate composition of some galactomannans from legume seeds and the percentage of anhydromannose residues versus the anhydrogalactose residues.
  • the percentage of anhydromannose may vary from about 50% to about 90% (e.g. 86%) of the composition of the galactomannan with the percent anhydrogalactose varying from about 10% (e.g. 14%) to about 50% .
  • TABLE 2 Approximate Composition of Some Galactomannans from Legume Seeds
  • Caesalpinia spinosa (tara) 71 26 Caesalpinia cacalaco (huizache) 69 28 Ceratonia sUiqua (carob, locust bean) 80-86 20-14 Cercidium torregyanum (palo verde) 73 22 Delonix regia (flame tree) 79 19 Cyamopsis tetragonolobus (guar) 64 36 Gleditsia triacanthos (honey locust) 71 26 Gymnocladus dioica (Kentucky coffee) 71 26 Sophora japonica 81 16
  • Desmanthus illinoensis (prairie-mimosa) 70 26 Indigofera hirsuta (indigo) 72 23 Cassia leptocarpa (senna) 65 21 Crotalaria intermedia (rattlebox) 64 28 Crotalaria juncea (rattlebox) 60 - Crotalia striata (rattlebox) 60 - Trigonella foenum graecum (fenugreek) 52 48 Medicago sativa (alfalfa) 66 33
  • the galactomannan that is most useful in this invention is derived from the cyamopsis tetragonolobus, commonly referred to as guar.
  • guar This exhibits a percentage mannose residue of about 64% with a percent galactose residue of about 36%.
  • Commercially available guar gum is about 66-82% galactomannan polysaccharide with protein, fat-extractable material, ash, moisture and other impurities making up the remainder of the composition.
  • guar is available commercially in purities that meet NF requirements, namely it may contain up to 15 % w water, 10% w protein, up to 7% w acid insoluble material and up to about 1.5 % ash.
  • the amount of the hydrocoUoid in the composition will be an amount that provides a mucosal protective effect as compared to a formulation of the drug which gives a standard release profile.
  • Mucosal protection is also sometimes referred to as cytoprotection if the mechanism by which a composition works to protect the mucosal layer is at the cell level.
  • mucosal protective will be used as the mechanism of action is not known for certain to be at the ceUular level where the protection is occurring. Mucosal protective more accurately reflects the protection of mucous layer of the stomach, i.e. gastric irritation is reduced.
  • Gastric irritation includes such adverse gastrointestinal (GI) side effects such as bleeding, ulceration and perforation of the mucosal Uning of the stomach and upper GI tract.
  • Mucosal protection is the abUity of a composition to defend against or prevent gastric mucosal lesions or damage that might occur as a result of NSAID administration.
  • the amount of the hydrocoUoid obtainable from higher plants that provides mucosal protection will be from about 15% by weight to about 90% by weight, based on the total pharmaceutical composition.
  • the amount of the hydrocoUoid will be between about 20% by weight to about 75% by weight, and more preferably about 40% by weight to about 60% by weight.
  • guar gum is a particularly preferred hydrocoUoid which is particularly useful in the various aspects of this invention.
  • the particle size of the hydrocoUoid, particularly guar gum, used in the composition will have a median diameter size of more than about 125 microns ( ⁇ ), i.e., about 50% of the particle mass in the composition be below 125 ⁇ in diameter and about 50% of the particle mass will be above about 125 ⁇ diameter.
  • the median particle size of the hydrocoUoid will be more than about 150 ⁇ with a distribution of about 75 to about 300 ⁇ . More preferably, the particles will be greater than 150 ⁇ up to 300 ⁇ , i.e. about 90% of the particle mass will have a particle size of 125 ⁇ or more, up to about 300 ⁇ .
  • Sources of guar gum are readily available commercially, but the brand referred to as SUPERCOL ® G3, having a particle size of about 75 to about 300 microns is found to be particularly useful.
  • the SUPERCOL guar gum is avaUable from the Aqualon Company, WUmington, Delaware.
  • Other sources include Henkel, a division of Emery Group, Cincinnati, OH or the Meer Corporation.
  • the desired particle sizes can be obtained by milUng larger particles of guar gum and sifting to get particles to the desired size, or sifting to obtain larger particle sizes.
  • the size distribution of the particles may be determined by standard sieve separation methods, i.e., by passing the guar particles though sieves having known mesh sizes (and known apertures) and coUecting the retained or non-retained fractions. The same methods are useful for obtaining guar particles of desired sizes for use in preparing the composition of the invention.
  • the release characteristics of the composition of this invention may be varied.
  • the smaller the particle size the slower the NSAID is dispersed.
  • the larger (or coarser) the particle size the more quickly is the NSAID dispersed.
  • the pharmaceutical composition of this invention is a particle mass of a solid dosage form that is administered orally.
  • the composition is neither a liquid nor a gas, but a solid which may be a powder for suspension in water, a tablet or a capsule, preferably the latter two.
  • the total amount in the solid dosage form will be that amount referred to as a unit dosage.
  • a capsule or tablet this will be an amount that can be swallowed by a human subject and may vary from a total of about 100 miUigrams to about 1500 mg, preferably no more than about 1200 mg and particularly no more than 1000 mg.
  • the tablet or capsule will be at least about 350 mg for enough of the hydrocoUoid to be present to provide a mucosal protective effect.
  • a unit dosage it is preferred to have about 240 milligrams of the hydrocoUoid such as guar gum but generally less than about a gram.
  • the size of the tablet or capsule may be significantly less than for adults, and for elderly patients who have difficulty swallowing, the total amount may be less than what would be viewed as a normal amount for adults.
  • the total amount of material in a unit dosage depends in part on the activity of the drug used in the composition.
  • a particularly useful composition for patients who have difficulty swaUowing piUs is one that is a unit dosage suitable for suspension in about an 8 ounce glass of water. This unit dosage amount is generally less than about 5 grams, preferably less than about 2.5 grams.
  • the therapeutically-effective amount of the NSAID in the unit dosage form w l be that amount of material which is calculated to give the desired therapeutic effect upon oral administration of the material. If the NSAID is highly active (or is like aspirin for low dosage treatment to prevent stroke or thromboses) and very little of the material is needed, then the total size of the unit dosage form will be less than if the drug requires a larger amount to get the desired physiological effect.
  • the amount of NSAID in the composition depends on the activity of the NSAID and this amount may vary from about 0.1 % weight to about 75% weight, generally in a tablet or capsule unit dosage form no more than about 45 % weight, preferably about 5 % to about 45 % by weight (generally no more than 35 % weight) and more preferably from about 10% weight to about 25 % weight.
  • a non-tablet or non-capsule unit dosage form e.g. , a powder for suspension in water the percent weight active will be about 10% to about 75 % by weight, preferably about 15 % to about 50% by weight.
  • NSAIDs may be employed, but the subject formulations find particular physiological advantage with aspirin.
  • NSAIDs and families of NSAIDs useful in the compositions of this invention include the salicylates, pyrazolons, indomethacin, sulindac, the fenamates, tolmetin, propionic acid derivatives, and the like.
  • Specific compounds include sabcylic acid, aspirin, methyl salicylate, diflunisal, salsalate, phenylbutazone, indomethacin, oxyphenbutazone, apazone.
  • mefenamic acid meclofenamate sodium, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, piroxicam, diclofenac, etodolac, ketorolac, aceclofenac, nabumetone, and the like.
  • Aspirin is preferred.
  • the weight ratio of the NSAID to the hydrocoUoid is a ratio of about 1:0.6 to 1:500.
  • the weight ratio of the drug to said hydrocoUoid of from about 1:1 to 1:15 and more preferably from about 1:1 to 1:3.
  • compositions that do not alter the pharmacokinetic profiles (i.e. the rate and extent of absorption) of the NSAIDs (e.g. aspirin) significantly in comparison to less or non-mucosally-protective commerciaUy -available products.
  • the composition wiU be designed to either disperse rapidly or swell to release the NSAID quickly.
  • the exact characteristics of the composition may be adjusted by the inclusion of the other dispersion-enhancing excipients. Other such excipients are included in the composition of this invention to help improve dispersion, i.e., disintegration of the composition to avoid the concentration of a NSAID in one place.
  • excipient may include all excipients present in the dosage form, including all components other than the drug entity and the hydrocoUoid gum from higher plants.
  • a plurality of excipient substances may be present in any dosage form, and may include multiple substances having similar pharmaceutical function (e.g., lubricants, flavorants, disintegrants, binders, diluents) or similar structure (e.g., a mixture of monosaccharides).
  • excipients are present in an amount sufficient to provide the composition with the desired characteristics, i.e. to enhance dispersion of the drug and hydrocoUoid, and will generally be present at a level of about 5% by weight to about 75% by weight, preferably about 10% by weight to about 50% by weight and more preferably about 10-25% by weight. For a dosage suitable for suspension no more than about 5% to 10% by weight is needed.
  • Excipients may be selected from many categories known in the pharmaceutical arts, but generally will be hydrophilic entities that absorb water readily and dissolve or that expand upon contact with water to aid in dispersion.
  • the former include carbohydrates such as mono- and disaccharides (i.e., lactose, sucrose, glucose, fructose, galactose); oligosaccharides such as dextrin; hydrocoUoid polysaccharides such as cellulose, microcrysta ine cellulose, semisynthetic ceUulose ethers and derivatives thereof such as, carboxymethylcellulose (CMC), carboxypolymethylenecellulose (CPMC), hydroxypropylceUulose (HPC), hydroxypropylmethylceUulose (HPMC), sodium CMC, and methylceUulose (MC); polyvinylpyrolidone (PVP), crospovidone (a crosslinked PVP), sodium starch glycolate, and coUoidal sUicon dioxide, represented by Syloid ® brand colloidal
  • NSAID include the following, which may be used alone or in combination with each other: Avicel ® brand microcrystaUine cellulose, Crospovidone ® brand PVP, lactose, Explotab ® brand sodium starch glycolate (in small quantities and generally combined with another excipient), Syloid ® brand colloidal silicon dioxide, and the like.
  • excipients such as other hydrocolloids
  • combinations of hydrocolloids may provide for greater degrees of control over drug delivery, but care must be taken in preparing the combinations, since depending upon the other excipients, there may be adverse effects. The adverse effects may include incomplete hydration. drug-dumping, and the like.
  • the amount and choice of the excipients will also be affected by the other ingredients present in the formulation, so that one may modulate the effects of the other hydrocolloids by the other components.
  • Another category of carbohydrates useful as another dispersion-enhancing excipient is the "lower organism" hydrocolloidal gums from bacterial, fungal, or algal sources, such as agar, xanthan, and carrageenan. These may be used in conjunction with the highly viscous hydrocolloidal gums from higher plants, such as guar, as described herein. When such lower organism gums are included, they generally wiU be present in amounts no greater than the amount of gum from higher plants, on a weight basis, and usuaUy no greater than 75 % , often 50%, less than 10-25%, of the amount of hydrocoUoid gum from higher plants.
  • a binder tends to bind or aggregate particles, and are often employed in tabletting to reduce friabUity and impart hardness to the composition. Thus careful consideration must be given to the amount of binder present so that the dispersion-enhancing aspect of the composition is not significantly reduced whUe at the same time improving hardness.
  • the hardness rating of a tablet will be sufficient for the tablet to be stored, handled, packaged and shipped without damaging a significant percentage of tablets in the overaU processing steps. UsuaUy the minimum hardness rating is about 6 kP and preferably is about 8 kP or more.
  • binders are described in numerous sources, e.g., Remington's Pharmaceutical Sciences. Strong binders in general wUl be employed in small proportions, usually less than about 10% wt, often less than about 5 % wt, frequently less than about 2 % wt, and occasionally less than 0.5 % of the weight of the dosage form.
  • An exemplary group of strong binders are carboxypolymethylene, referred to as CARBOPOL and CARBOMER. In large amounts, they interfere with disintegration of the dosage forms, and should be used in small proportions or avoided altogether.
  • Non-gas-forming filler materials or diluents are typically inert substances for dispersing the compound within the particle mass while being conducive to hydration of the mass during migration through the stomach. Such a diluent may simply serve to dilute the drug and aid in processing and/or dispersion of the NSAID.
  • Mineral salts that dissolve in gastric juice may be used, thereby aiding in the disintegration of the dosage form and hydration of the hydrocolloids.
  • salts which form gas in the gut such as carbonates and bicarbonates, had been shown to be needed in dosage forms with guar gum.
  • the present invention may employ non-gas-forming mineral salts such as alkaline earth (e.g. , Ca +2 , Mg +2 ) phosphates and sulfates, but preferably the composition of this invention is free of any gas-forming mineral salts because they generally absorb water readily and make the compositions more difficult to handle and store.
  • excipients may be included to impart lubricating properties to the composition to aid in release from tabletting press or to assist in making the composition flow better.
  • Such components include fatty acids or their salts (e.g. , stearic acid or magnesium stearate) and waxes.
  • excipients may include synthetic emulsifiers (e.g. , sodium lauryl sulfate) and surfactants, such as polyakylene glycols (e.g. , polyethylene glycol-PEG).
  • the amount of polyethylene glycol may be restricted to be present in less than 20% relative to the weight of the drug, particularly with PEGs of mean molecular weight greater than 2,000 Daltons.
  • compositions of this invention that are useful for tablet and capsule formulations.
  • the table shows the approximate relative weight percent of each component that may be used. It is to be understood that the total amount in the composition is a unit dosage that may vary between about 100 mg and about 1500 mg, but generally wiU be less than 1200 mg and preferably less than about 1000 mg.
  • the "hydrocoUoid" in the first column refers to a hydrocoUoid gum obtainable from higher plants in accordance with this invention. This may be a gum having a preferred particle size as discussed herein, preferably between about 150 ⁇ to about 300 ⁇ .
  • the excipient may be a single excipient or a mixture of excipients as discussed hereinbefore. The numbers are simply meant to be approximation of the proportions of components used.
  • the particle mass is blended by standard methods, i.e. , by combining the specified components and mixing them in a granulator or other type of blender.
  • the particle mass described in hereinbefore may be bound together by encapsulation or compacted as a tablet, optionally coated with a non-enteric coating material.
  • the tablet or capsule is prepared so as to (i) prevent dispersal of the particle mass until the particle mass has reached the stomach, (ii) to dissolve in the stomach in a manner that allows a hydrated gel layer to form around the entire particle mass, forming a guar-compound bolus, and (ni) to dissolve relatively quickly after the hydrated gel layer has formed to allow compound release from the bolus.
  • the holding means is a capsule, such as a gelatin capsule available from Elanco Qualicaps (Indianapolis, IN) or Capsugel (Warner Lambert, Morris Plains, NJ).
  • a capsule such as a gelatin capsule available from Elanco Qualicaps (Indianapolis, IN) or Capsugel (Warner Lambert, Morris Plains, NJ).
  • Other suitable capsules include soft elastic capsules.
  • the particle mass Prior to encapsulation or coating, the particle mass can be gently compressed in a dry granulation process to facilitate manufacture or to modify dissolution properties of the mass. This process leads to formation of tablet triturates.
  • the composition of the particle mass is generally the same as for the encapsulated forms described above.
  • the tablet is formed by conventional means, at a compression pressure of about 3,000 to about 5,000 psi.
  • the tablet should be sufficiently cohesive to aUow formation, in the stomach, of a hydrated gel layer which coats the surface of the tablet and keeps the tablet together as a single bolus until the tablet becomes fully hydrated and fully dispersed.
  • the tabletted particle mass can be coated with a coating, e.g., lactose or cellulose derivatives that improve the ease of swallowing, prevent swelling and improve the pharmaceutical appearance.
  • a coating e.g., lactose or cellulose derivatives that improve the ease of swallowing, prevent swelling and improve the pharmaceutical appearance.
  • Such coatings can be simple sugars such as lactose, sucrose and the like or may be high viscosity hydrocoUoid or other, particularly lower viscosity, hydrocoUoids, particularly ionic hydrocolloids, more particularly cellulosic derivatives, such as ethyl ceUulose.
  • a hydrocoUoid may be used by itself or in conjunction with a neutral ceUulosic hydrocoUoid.
  • the coating may be achieved in a fluid bed granulator prior to packaging.
  • composition of this invention is particularly effective as a powder in a unit dosage form that is suitable for adding to water to form a suspension.
  • the hydrocoUoid will be of lesser viscosity so that the aqueous suspension is not too thick.
  • a hydrocoUoid such as guar gum having coarser particles and lower viscosity is preferred as the hydrocoUoid.
  • An example is SUPERCOL G3 guar gum (particle size distribution of about 75 microns to about 300 microns with a median particle size above about 150 ⁇ ).
  • the unit dosage amount as a powder suitable for suspension will be about 800 mg to about 5 grams, generally less than about 4 grams, and preferably less than 2.5 grams.
  • the NSAID e.g., aspirin
  • hydrocoUoid being present in an amount from about 20% to about 90% by weight, preferably about 50% to 85 % by weight
  • the other excipient e.g., flavoring, flavor aids, sugar, etc.
  • compositions according to this invention are prepared by thoroughly mixing the components of the composition of this invention and preparing a unit dosage form that is suitable for oral administration and that exhibits a mucosal protective effect to a subject to whom it is administered.
  • the components are mixed as dry, paniculate material in the preparations and having the particle size distribution set out hereinbefore to give a composition with the components uniformly distributed throughout the composition.
  • the mixing is achieved using standard mixing technology known in the art such as that set forth in Remington's (Eighteenth Edition) at pp. 1627-1629.
  • Representative equipment includes rotating-shell mixers (e.g.
  • a cross- flow blender a cross- flow blender
  • fixed sheU mixers MuUer mixers
  • vertical impeUer mixers motionless mixers and the like.
  • the resulting mixture is then prepared as a unit dosage, e.g. , as a tablet or, preferably, as a capsule in accordance with known techniques such as those set forth in Remington's (Eighteenth Edition) in Chapter 89, which is incorporated herein by reference.
  • compositions of this invention can be prepared.
  • the components of the NSAID and the hydrocoUoid are thoroughly mixed with the dispersion-enhancing excipient as discussed herein before.
  • the resulting blend is compressed to form large caplets having an average hardness rating of about 8-12 Kp, preferably about 10 Kp.
  • These caplets are then crushed and sieved using an 18 and 40 mesh screen, and the particles that are retained on the 40 mesh screen (e.g. , particles of 425 ⁇ size but generally between about 400-500 ⁇ ) are then combined with a lubricant and tabletted.
  • Another aspect of this invention may be viewed as an improvement.
  • a process of preparing an orally administrate dosage form of an NSAID suitable for human administration that comprises combining a therapeutically effective amount of the NSAID with suitable pharmaceutical excipients
  • the improvement that comprises combining the NSAID with a powdered hydrocoUoid gum obtainable from higher plants in an amount sufficient to reduce the ulcerogenic effect of the NSAID.
  • Still another aspect of this invention is a method of orally administering an NSAID to a mammaUan subject (preferably human) in need thereof wherein the drug is orally deUvered in a unit dosage as a composition of this invention.
  • Another way of viewing the method this invention is as an improvement.
  • the improvement comprising orally administering the NSAID in combination with a powdered hydrocoUoid gum obtainable from higher plants in an amount sufficient to provide a mucosal protective effect for the subject.
  • that amount sufficient to provide such a mucosal protective effect is set forth hereinbefore in the discussion of the composition of this invention.
  • the dosages for NSAIDs may be readily found in the "Physician's Desk Reference" or in "Goodman and Gilman,” and as such they are incorporated herein by reference.
  • This example shows the mucosal protective effect of a hydrocoUoid gum obtainable from higher plants (guar gum) in an NSAID (aspirin) formulation administered to rats.
  • the treatments were prepared immediately prior to use.
  • the aspirin treatments were prepared by suspending 2.00 grams of fine mesh aspirin in 100 ml water (plus 0.1 % Tween 80) and then adding the specified amount (i.e. 0, 0.10, 1.00, or 5.00 grams) of
  • Guar gum The Guar gum 5.0% alone treatment was prepared as above except the aspirin was omitted. A dosing preparations were warmed to about 100°C; uniformity of suspensions was ensured by constant stirring.
  • Sprague-Dawley male rats 148 to 190 grams, were individually-housed under standard Vivarium conditions. After arrival, rats were allowed to acclimate in house for a minimum of 5 days before initiation of testing. Rats were fasted (water ad libitum) for 18 hours prior to testing. Treatments 1-6, assigned to rats in random fashion, were administered orally (gavage) at the rate of 10 ml/kilogram (kg).
  • each rat was sacrificed by carbon dioxide inhalation. The abdomen was opened. The stomach was removed, opened along the greater curvature, examined for the presence of lesions, and assigned a severity grade according to the following scale: 0 No lesions
  • results presented as means ⁇ s.e.m., are summarized in Table 3.
  • the results show that guar gum protects against aspirin-induced gastric lesions.
  • mean ulcer severity was 5.8.
  • rats receiving guar gum 0.1 % , 1.0%, and 5.0% , respectively, mean severities were 4.0, 3.6, and 2.7.
  • reductions in ulcer severity were 30, 38, and 54 percent, respectively. All differences were statistically significant (p ⁇ 0.05).
  • This example shows the mucosal protective effect (i.e. the reduction of gastrointestinal irritancy) of a hydrocoUoid gum obtainable from higher plants (guar gum) in NSAID (aspirin) formulation administered to humans.
  • NSAID aspirin
  • Treatment B Aspirin 650 mg/0.1 wt % guar gum (Powder)
  • Treatment D Aspirin 650 mg/1.4 wt % guar gum (Powder)
  • Endoscopy was used to assess the extent and severity of gastric and duodenal damage.
  • the number and location of submucosal hemorrhages, erosions, and ulcerations were determined by the endoscopist, who was unaware of the formulation administered to the subjects. Based on these findings, the menonhagic damage was graded on a 0-4 scale and the erosive damage was graded on a separate 0-4 scale.
  • the stomach and duodenum were graded separately. Endoscopy was performed 4 hours after the first does on Day 1 to assess acute irritancy and on Day 4 to assess overall, or "pharmacological" steady-state, irritancy. Plasma concentrations of acetylsalicylic acid and salicylic acid were used to assess absorption of the aspirin from the test formulations.
  • the Kruskal-WaUis test was used to compare the distribution of scores across treatments. WUcoxon's Rank Sum test was used for pairwise comparisons between each of the aspirin/guar formulations vs. aspirin alone. When grouping the scores to determine the presence vs. absence of irritancy and sever vs. nonsevere damage, the Mantel-Haenszel test was used to test for a decrease in irritation with increasing guar dose. Fisher's Exact test was also used to determine pairwise differences between the aspirin/ 1.4% guar dose vs. aspirin alone.
  • the aspirin/guar formulations have an improved benefit/risk profile compared with aspirin alone.
  • compositions of this invention that contain a hydrocoUoid from higher plants (guar gum) in a mucosally protective amount, a NSAID (aspirin- AS A), and other excipients.
  • a hydrocoUoid from higher plants guar gum
  • NSAID aspirin- AS A
  • the composition should have a disintegration time (DT) of less than about 5 minutes (preferably less than about 2 minutes and more preferably less than about 1 minutes) and a hardness rating of about 5 or more, preferably about 7 or more, most preferably about 9 or more.
  • compositions were prepared having the components speUed out in Tables 8 and 9.
  • the aspirin was initially sieved through a 40 mesh screen.
  • the powders were weighed to produce 30 gram batch sizes and mixed manually using geometric dilution.
  • the tablets were compressed manually as well using a Stokes B-2 rotary tablet press.
  • the percentages are given in Table 8 and the difference was substituted with guar when necessary.
  • the formulations following CP-04-18 were made to determine if the overaU weight of the aspirin tablets could be reduced. Additional excipients that were evaluated include Avicel PH302, Syloid and sodium lauryl sulfate. Tablets were made to either 1 gm, 950 mg, 900 mg, or 850 mg in size. AU of the tablets were designed to contain 325 mg of ASA and 500 mg of guar in each. The individual ingredients and the tablet weights are summarized in Table 9. In formulations 18-21 , the amount of guar and aspirin per tablet was kept constant, while the Crospovidone decreased. Other formulations included Crospovidone and Avicel combined with either Explotab (sodium starch glycolate) or Ac- Di-Sol ® (sodium carboxymethylcellulose) at 2 and 4%.
  • Explotab sodium starch glycolate
  • Ac- Di-Sol ® sodium carboxymethylcellulose
  • Dry granulation was also evaluated for CP-04-19. Guar (Tic 822/A from the TIC Gum, Co.) and ASA portions were preweighed and mixed together. Large caplets of the mixture were compressed to a hardness averaging 10 Kp. Formulation CP-04-49 and CP- 04-50 used a dry granulation of ASA and guar with and without crospovidone. The caplets were carefully crushed with a mortar and pestle and periodically sieved through an 18 and 40 mesh screen. The granules remaining on the 40 mesh screen were combined with the other ingredients. Once the first group of formulations were made they were tested for disintegration times (DT) under static conditions.
  • DT disintegration times
  • the tablets were placed in Bio-Dis dissolution vessels containing 100 ml USP simulated gastric fluid without enzymes (SGF) at 37°C. Without the dipping mechanism activated, the times for the tablets to disintegrate were recorded. Once a tablet appeared to be gone, the vessel was swirled to determine if a core was remaining. If a core was visible, the time was recorded once the core disappeared. Some formulations were also evaluated for disintegration times using the paddle method. The paddle speed was set to 50 rpm and the time to apparent disintegration was recorded. These were done in 500 ml of SGF at 37 °C.
  • SGF simulated gastric fluid without enzymes
  • compositions in Table 8 have the favorable characteristics needed to be included in the compositions of this invention.
  • composition #CP-04-03, -04 and -05 exhibit disintegration times that are too high because the excipient is not sufficiently dispersion-enhancing.
  • combination with other components and in smaller amounts as in composition #CP-04-12, -22, -24, -26, -28, -30, -32, -34 and -36 these components can be used.
  • the following formulations contain 32.5% ASA, 49.1 % G3 Guar, 0.4% Mg. Stearate unless otherwise noted. Tablet weights were 1 gm. Disintegration times (DT) were determined in SGF at 35 °C.
  • the foUowing formulations contain 34.2% ASA, 52.6% G3 Guar, 0.4% Mg Stearate unless otherwise noted. Tablet weights were 950 mg. Disintegration times (DT) were determined in hot tap water (35-40°C).
  • This example shows the mucosal protective effect of a hydrocoUoid gum obtainable from higher plants (guar gum) in an NSAID (ketoprofen) formulation and is similar to the tests done in Example 1.
  • ketoprofen 100 mg/kg was administered to rats to induce gastric damage and guar gum was coadministered to determine its effect. Both the ketoprofen and guar gum were administered as an aqueous mixture.
  • the animals were randomized into groups according to bodyweight using random numbers tables so that the group mean body weights were approximately equal. Including the day of randomization, there were a further 3 days of acclimatization prior to dosing. Within each case, each animal was individually identified by tail marking.
  • the dose formulations were prepared on the day of the test by suspending Ketoprofen in 0.1 % TWEEN 80. Guar gum was formulated in a ketoprofen suspension by vigorous stirring for 1 minute to achieve the required concentrations. Preparation and dosing were organized such that dosing of all animals within a treatment group was completed within three minutes of preparing the formulation.
  • the rats were fasted for approximately 18 hours prior to the test; water was available ad libitum. During this time the rats were housed singly in a room maintained at a temperature of approximately 16°C. On the day of the test the rats were orally dosed with either vehicle or test article at a constant dose volume of 10 ml/kg, according to the following treatment table:
  • vehicle group and treatment groups were compared using analysis of variance or by using Student's t test.
  • Ketoprofen 100 13.1 3 Ketoprofen + Guar Gum 0.1 % 100 + 0.1 % 15.3 + 16.8 4 Ketoprofen + Guar Gum 1.0% 100 + 1.0% 7.9 -39.7 5 Ketoprofen + Guar Gum 2.0% 100 + 2.0% 7.9 -39.7
  • simUar compositions of this invention are prepared for other NSAIDs such as saUcyUc acid, aspirin, methyl salicylate, diflunisal, salsalate, phenylbutazone, oxyphenbutazone, apazone, mefenamic acid, meclofenamate sodium, indomethacin ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, piroxicam, diclofenac, etodolac, ketorolac, aceclofenac and nabumetone.
  • NSAIDs such as saUcyUc acid, aspirin, methyl salicylate, diflunisal, salsalate, phenylbutazone, oxyphenbutazone, apazone, mefenamic acid, meclofenamate sodium, indomethacin ibuprofen, naproxen, naproxen sodium,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition pharmaceutique à administration par voie orale, destinée à réduire l'irritation gastrique due à un anti-inflammatoire non stéroïdien dans la partie supérieure du tube digestif d'un mammifère. La composition comprend (a) une gomme hydrocolloïdale acceptable sur le plan pharmaceutique pouvant être obtenue à partir des plantes supérieures, en quantité suffisante pour protéger les muqueuses, (b) un autre excipient en quantité suffisante pour favoriser la dispersion, et (c) un anti-inflammatoire non stéroïdien en quantité suffisante pour posséder une action thérapeutique. Sont aussi présentés une technique de préparation de la composition et un procédé visant à réduire, par administration de la composition, l'irritation gastrique due à un anti-inflammatoire non stéroïdien. Est également présentée une composition particulièrement utile pour la préparation d'une suspension aqueuse.
EP95944048A 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures Withdrawn EP0804169A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34760194A 1994-12-01 1994-12-01
US347601 1994-12-01
PCT/US1995/015599 WO1996016639A1 (fr) 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures

Publications (2)

Publication Number Publication Date
EP0804169A1 true EP0804169A1 (fr) 1997-11-05
EP0804169A4 EP0804169A4 (fr) 1998-08-19

Family

ID=23364417

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95944048A Withdrawn EP0804169A4 (fr) 1994-12-01 1995-11-30 Apport d'un anti-inflammatoire non steroidien au moyen d'une gomme hydrocolloidale en poudre pouvant etre obtenue a partir des plantes superieures

Country Status (8)

Country Link
EP (1) EP0804169A4 (fr)
JP (1) JPH10509982A (fr)
AU (1) AU690417B2 (fr)
CA (1) CA2205442C (fr)
FI (1) FI972305A (fr)
MX (1) MX9704079A (fr)
NO (1) NO972485L (fr)
WO (1) WO1996016639A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP0859603B1 (fr) * 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Matrice a liberation prolongee pour medicaments insolubles en doses elevees
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
CA2338794C (fr) * 1998-08-21 2009-01-20 Novartis Ag Nouvelle formulation orale d'agonistes ou d'antagonistes de 5-ht4
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2143059A1 (fr) * 1971-06-19 1973-02-02 Merck Patent Gmbh
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
WO1986006627A1 (fr) * 1985-05-15 1986-11-20 Riker Laboratories, Inc. Procedes et compositons de theophylline a liberation entretenue
WO1994015643A1 (fr) * 1992-12-30 1994-07-21 Fmc Corporation Excipient a liberation, prolongee, facile a produire, a base de glucomannane de konjac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
FR2143059A1 (fr) * 1971-06-19 1973-02-02 Merck Patent Gmbh
WO1986006627A1 (fr) * 1985-05-15 1986-11-20 Riker Laboratories, Inc. Procedes et compositons de theophylline a liberation entretenue
WO1994015643A1 (fr) * 1992-12-30 1994-07-21 Fmc Corporation Excipient a liberation, prolongee, facile a produire, a base de glucomannane de konjac

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9616639A1 *

Also Published As

Publication number Publication date
JPH10509982A (ja) 1998-09-29
CA2205442A1 (fr) 1996-06-06
FI972305A0 (fi) 1997-05-30
NO972485D0 (no) 1997-05-30
MX9704079A (es) 1997-12-31
FI972305A (fi) 1997-05-30
AU4595196A (en) 1996-06-19
WO1996016639A1 (fr) 1996-06-06
AU690417B2 (en) 1998-04-23
CA2205442C (fr) 2003-01-21
NO972485L (no) 1997-07-31
EP0804169A4 (fr) 1998-08-19

Similar Documents

Publication Publication Date Title
US5023245A (en) Improved niacin formulation
EP0322222B1 (fr) Formes d'administration de médicaments à effet prolongé à base d'hydroxypropylméthylcellulose et de sels de métaux alcalins d'acides carboxyliques
US5096714A (en) Prolonged release drug tablet formulations
EP0234670B1 (fr) Formulation pharmaceutique à libération retardée contenant de la gomme xanthane
EP0157695B1 (fr) Formes de dose solides d'un médicament à libération contrôlée à base de mélanges d'éthers cellulosiques hydrosolubles et de tensioactifs anioniques
AU745682B2 (en) Rapidly disintegrating methylcellulose tablets
AU741326B2 (en) Rapidly disintegrating methylcellulose tablets
AU772891B2 (en) Sustained release tablet containing hydrocolloid and cellulose ether
US5445826A (en) Delivery system containing a gel-forming dietary fiber and a drug
US6129930A (en) Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
PL177315B1 (pl) Lek w postaci tabletek o przedłużonym uwalnianiu substancji czynnej
AU690417B2 (en) Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5993860A (en) NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
AU709413B2 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
JPS6087216A (ja) 一定放出性固体投薬形インドメタシン組成物および関節炎その他の炎症性状態の治療法
MXPA97004043A (en) Assortment of pharmacy of sustained release using a rubber of hydrocoloid in powder obtained from top plants
CA2030448A1 (fr) Formulation pour melange de boisson a la niacine
AU609234B2 (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US20080045573A1 (en) Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
CA2030449A1 (fr) Formule pour comprimes medicamenteux a liberation progressive
HUE033619T2 (en) Mizoprostol dispersible tablet
JPH0532373B2 (fr)
MXPA01006202A (es) Formulacion de liberacion controlada de sodio de divalproex
AU2009200874A1 (en) Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
MXPA00001856A (en) Rapidly disintegrating methylcellulose tablets

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980706

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000601